• Rallybio agreed to acquire Avenzo in a merger; the combined company is expected to operate as Avenzo Therapeutics and trade as AVZO.
• Avenzo arranged a concurrent oversubscribed private placement of USD 215 million to fund development of four clinical-stage oncology programs.
• Closing is expected in Q4 2026; Rallybio plans to distribute substantially all pre-closing net cash to its stockholders.
• Post-close ownership is expected at about 2.8% for pre-transaction Rallybio holders, about 97.2% for Avenzo holders including financing investors.
• Rallybio stockholders will also receive CVRs tied to net cash proceeds from the prior REV102 interest sale and potential dispositions of other legacy assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260531328050) on June 01, 2026, and is solely responsible for the information contained therein.